Ranjita Shegokar - Böcker

Delivery of Drugs: Expectations and Realities of Multifunctional Drug Delivery Systems, Volume Two examines the formulation of micro-nanosized drug delivery systems and recaps opportunities for using physical methods to improve efficacy via mechano-, electroporation. The book highlights innovative delivery methods like PIPAC, including discussions on the regulatory aspects of complex injectables. Written by a diverse range of international researchers from industry and academia, the chapters examine specific aspects of characterization and manufacturing for pharmaceutical applications as well as regulatory and policy aspects.This book connects formulation scientists, regulatory experts, engineers, clinical experts and regulatory stakeholders. This level of discussion makes it a valuable reference resource for researchers in both academia and the pharmaceutical industry who want to learn more about the status of drug delivery systems. Delivery of Drugs examines the fabrication, optimization, scale-up, biological aspects, regulatory and clinical success of various micro and nano drug delivery systems. The volume covers site and organ specific targeting approaches, technologies used in preparation of micro - nanoparticles, challenges of complex type of drug delivery forms and role of physical methods in achieving targeted drug effect. Written by a diverse range of international researchers the chapters examine the specific aspects of characterization and manufacturing of drug delivery system for pharmaceutical application and its regulatory aspects The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers Expectations and Realities of Multifunctional Drug Delivery Systems connects formulation scientists, regulatory experts, engineers, clinical experts and regulatory stake holders. The wide scope of the book ensures it as a valuable reference resource for researchers in both academia and the pharmaceutical industry who want to learn more about drug delivery systems

Nanopharmaceuticals reviews advances in the drug delivery field via nanovehicles or nanocarriers that offer benefits like targeted therapy and serves as a single dose magic bullet for multiple drug delivery with improved drug efficiency at a lower dose, transportation of the drug across physiological barriers as well as reduced drug-related toxicity. The chapters are written by a diverse group of international researchers from industry and academia.

The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.

Expectations and Realities of Multifunctional Drug Delivery Systems connects formulation scientists, regulatory experts, engineers, clinical experts and regulatory stake holders. The wide scope of the book ensures it as a valuable reference resource for researchers in both academia and the pharmaceutical industry who want to learn more about drug delivery systems.

Other volumes in the Expectations and Realities of Multifunctional Drug Delivery Systems book series:

Delivery of Drugs, Volume 2, 9780128177761

Drug Delivery Trends, Volume 3, 9780128178706

Drug Delivery Aspects, Volume 4, 9780128212226

Encompasses functional aspects of nanocarriers Discusses Intellectual Property landscapes of micro-nano drug carriers Contains in-depth investigation of specific aspects of drug delivery systems

Drug Delivery Trends examines a drift in the pharmaceutical field across the wide range of dosage forms, drug delivery systems (micro and nanoparticulate), at the regulatory front and on new types of therapies in the market. This volume additionally covers the challenges on drug delivery systems in terms of preclinical and current ways of determining quality and the options to solve the challenges associated with this. Most small-medium scale industries and academics struggle with initial regulatory challenges so a detailed discussion on regulatory trend covers the necessary basic understanding of regulatory procedures and provides the required guidance.

The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.

Expectations and Realities of Multifunctional Drug Delivery Systems connects formulation scientists, regulatory experts, engineers, clinical experts and regulatory stake holders. The wide scope of the book ensures it as a valuable reference resource for researchers in both academia and the pharmaceutical industry who want to learn more about drug delivery systems.

Encompasses trends in drug delivery systems and selected dosage forms Illustrates regulatory, preclinical and quality principles Contains in-depth investigation of upcoming types of drug delivery systems

Drug Delivery Aspects reviews additional features of drug delivery systems, along with the standard formulation development, like preclinical testing, conversion into solid dosage forms, roles of excipients and polymers used on stability and sterile processing. There is a focus on formulation engineering and related large scale (GMP) manufacturing, regulatory, and functional aspects of drug delivery systems. A detailed discussion on biologics and vaccines gives insights to readers on new developments in this direction.

The series Expectations and Realities of Multifunctional Drug Delivery Systems examines the fabrication, optimization, biological aspects, regulatory and clinical success of wide range of drug delivery carriers. This series reviews multifunctionality and applications of drug delivery systems, industrial trends, regulatory challenges and in vivo success stories. Throughout the volumes discussions on diverse aspects of drug delivery carriers, such as clinical, engineering, and regulatory, facilitate insight sharing across expertise area and form a link for collaborations between industry-academic scientists and clinical researchers.

Expectations and Realities of Multifunctional Drug Delivery Systems connects formulation scientists, regulatory experts, engineers, clinical experts and regulatory stake holders. The wide scope of the book ensures it as a valuable reference resource for researchers in both academia and the pharmaceutical industry who want to learn more about drug delivery systems.

Encompasses engineering and large-scale manufacturing of nanocarriers Considers preclinical, regulatory and ethical guidelines on nanoparticles Contains in-depth discussions on delivery of biologics, vaccines and sterilisation Industrial view on solid dispersions, milling techniques

Emerging Nanotechnologies in Immunology aims to deliver a systematic and comprehensive review of data concerning the nature of interaction and nano-related risks between the nanophamaceuticals currently in the pipeline of S&T development for skin, ocular, and nasal drug delivery, including absorption, toxicity, and the ability to distribute after systemic exposure.The scientific development of manufactured nanomaterials for drug delivery is increasing rapidly. One of the most prominent applications is topical drug delivery, where cutaneous, ocular, and nasal exposure becomes even more relevant. These targets are the first barrier that nanoparticles encounter when in contact with the human body.The contributors addresses a representative set of the broad spectrum of nanopharmaceuticals currently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue engineered skin substitutes. Regulation and risk is also covered, since the safety of these nanophamaceuticals still represents a barrier to their wide innovative use. Provides the reader with a thorough knowledge of the safety aspects of nanopharmaceuticals which are currently under research Focuses on the characterization and quantification of the nanopharmaceuticals Allows readers to understand the correlation between the nature of the materials and their potential nanotoxicological effects Includes an overview of regulatory aspects related to the R&D of nanopharmaceuticals

"Cell niches� are present in several human body tissues as a dynamic microenvironment essential to modulate stem cells' behavior in health, under injury, and in regenerative processes. The interplay between stem cells and their niche is necessary for sustaining tissues. The extracellular matrix (ECM) is the crucial component of the stem cell. It defines the architectural space, physical binding to the cell membrane, and interactions with the neighborhood cells and supports physical stress. Domains with nano or micrometric sizes define the surface and topology of the ECM, mediating cell interactions and macrophage recruitment to injured sites.

Over the last two decades, the integration of biomedicine with other engineering and biomaterial sciences promoted the development of nanotechnology and regenerative medicine toward mimicking the specialized stem cell niches to treat diseases with less invasive and efficient therapies. Innovative approaches in nanotechnology, such as targeting the immunological system, transporting drugs across blood-brain/BBB and blood-retinal barriers/BRB, directing active moiety to specific disease location/organs, encapsulation of multiple components, and promoting signalization and pathway-specific surfaces for cell interactions and growth, are indeed promising. On the other side, developments of biomaterial scaffolds to mimic the cell niches for interactions with stem cells in vitro or in vivo have tremendous potential.

The three-dimensional printing technology offers a base for a wide array of applications, for example, developing tissue constructs, mimetic organs, organoids, and organ-on-a-chip, thus avoiding the differences between animal model species and humans. Aiming closer to the natural environments, fresh autologous products from the blood, such as platelet-rich plasma (PRP), contain platelets and leukocytes, providing growth factors, cytokines, and proteins for the resident stem cells in the stages of regeneration. PRP also provides pain relief, reducing disabilities in elderly or diseased people. This book brings thought-provoking multidisciplinary topics on the diverse aspects of basic and applied sciences. The prime focus of the compilation is to understand the challenges researchers encounter in combining nanotechnology and regenerative medicine, ultimately integrating both disciplines for the benefit of the patient and offering them a ray of hope to be cured.

Presents multi-disciplined knowledge on bench-to-bedside application of nanotechnology in regenerative medicines Highlights the fundamentals, frontiers, limitations, and challenges faced by regenerative medicines Exhibits synergy of biotechnology, nanomedicine, biomedicine, chemical-material engineering, pharmaceutical technology, and applied medical sciences in success of regenerative medicines�

Drug Delivery Landscape in Cancer Research examines the combined impact of prevention, diagnosis, and treatment of cancer. With a strong focus on the status, challenges, and prospects of cancer drug delivery technology, the book examines clinical translation-related knowledge and the development of different organ related cancers. In 22 chapters, it describes current and new drug delivery systems in twenty different cancers and gives insights into drug delivery strategies and tumor microenvironment management in oral and ocular cancers. This book is a timely and valuable resource for health professionals, scientists, researchers, health practitioners, students, and anyone who wants to broaden their knowledge.Contains current studies of the targeted use of drug delivery systems based on the microenvironmental properties of different cancer typesProvides essential information on the most recent drug delivery systems available for different cancer typesExplains current technology and its applications to drug delivery in cancerContains contributions from oncologists, biomedical engineers, pharmaceutical scientists, and manufacturers

Cancer, a multifaceted disease, remains the leading cause of death worldwide. Ongoing research and technological advancements are continually improving the human understanding of newer treatment options. This book series aims to provide wide-ranging insights into the current landscape of cancer research, highlighting the recent advancements, current challenges, and future directions. Cancer varies widely in its formation, microenvironment, location in the body, associated risk factors, detection methodology, and treatment approaches. Early detection and prevention through lifestyle changes, regular screenings, and the awareness of symptoms are crucial for improving outcomes and survival rates. In this book series, the main focus is on trending topics, like new drug delivery, diagnostics, biomarkers, and preclinical and clinical developments in cancer research. Nanotechnology has emerged as a transformative approach in medicine, particularly in the areas of targeted drug delivery systems, imaging, and diagnostics to enhance the therapeutic efficacy and minimize adverse effects in cancer therapy. Advances in pharma, medical device, and diagnostic research, including the development of Trojan-horse therapies and precision treatments/assay kits, continue to enhance the effectiveness of cancer care over the past few decades. A total of five books are covered in this series: Drug Delivery Landscape in Cancer Research (Vol. 1)Biomarker Landscape in Cancer Research (Vol. 2)Diagnostic Landscape in Cancer Research (Vol. 3)Preclinical Landscape in Cancer Research (Vol. 4)Clinical Landscape in Cancer Research (Vol. 5) By integrating basic, applied, and innovative science concepts, this book series fosters a deeper understanding of the disease and paves the way for the development of more effective strategies. This book series serves as a valuable resource for students, researchers, regulators, and clinicians interested in understanding the complexities of cancer and the innovative approaches researched to combat this deadly disease. Nonetheless, continuous interdisciplinary, cross-country collaborations and cross-science innovation strategies are essential to further reduce the global cancer burden.Contains current studies of the clinical research of different cancer typesProvides essential information on the most recent developments in clinical cancer researchExplains current technology and its applications of clinical cancer researchHolds contributions from oncologists, biomedical engineers, pharmaceutical scientists, and manufacturers

Preclinical Cancer Landscape discusses the issues in preclinical-to-clinical translatability of molecularly targeted cancer therapies and the need to better align tumour biology in patients With a strong focus on the status, challenges, prospects and the need of robustness of preclinical cancer research, the book acknowledges that the bar for reproducibility in performing and presenting preclinical studies must be raised to facilitate a transparent discovery process that frequently and consistently leads to significant patient benefit. In 22 chapters this book describes the current status of preclinical research in multiple cancers. This book is a timely and valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field. " Preclinical landscape in cancer research " is written by experts in the field and informed with facts directly from manufacturers. Pharmaceutical scientists, medical researchers, biomedical engineers and clinical professionals will find this an essential reference.Contains current studies of the preclinical research of 25 different cancer typesProvides essential information on the most recent developments in preclinical cancer researchExplains current technology and its applications of preclinical cancer researchHolds contributions from oncologists, biomedical engineers, pharmaceutical scientists and manufacturers

Diagnostic Landscape in Cancer Landscape examines the combined impact of prevention, diagnosis, and treatment of cancer. With a strong focus on the status, challenges, and prospects of diagnostic tools and technology, the book also examines the clinical translation-related knowledge and prognosis of different organ related cancers. In 22 chapters, the book describes current and new diagnostic tools in twenty different cancers and explores how innovations in the cancer diagnostic space could make cancer screening and early detection more straightforward.This book is a timely and valuable resource for health professionals, scientists, researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field.Provides essential information on the most recent developments in the diagnostic landscape of different cancer typesExplains current technology and its applications in the diagnostic cancer research landscapeIncludes contributions from oncologists, biomedical engineers, pharmaceutical scientists, and manufacturers

Biomarker Landscape in Cancer Research examines the impact of early detection, predication of aggressiveness, and the determination of the best treatment for cancers. With a strong focus on the status, challenges, and prospects of biomarker measurements' tools and technology, the book also examines clinical translation-related knowledge and the prognosis of different organ related cancers. In 21 chapters, it describes current and new diagnostic tools in twenty different cancers and explores how innovations in the cancer diagnostic space could make cancer screening and early detection more straightforward.This book is a timely and valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field.Provides essential information on the most recent developments in the biomarker landscape of different cancer typesExplains current technologies and their applications in the biomarker cancer research landscapeIncludes contributions from oncologists, biomedical engineers, pharmaceutical scientists, and manufacturers

Tumor Microenvironment provides an in-depth exploration of the intricate relationships between various cancers and their respective tumor microenvironments. Each chapter focuses on a specific type of cancer, detailing the unique characteristics of its microenvironment, including the roles of immune cells, stromal components, and extracellular matrix. The book highlights advancements in research, diagnostic techniques, and therapeutic strategies aimed at targeting the tumor microenvironment, offering valuable insights into potential future directions in cancer treatment. By presenting cutting-edge information and real-world applications, this book helps readers understand cancer biology while also fostering innovative approaches to research and clinical practice that contribute to improved patient outcomes.Provides an extensive examination of the tumor microenvironment across various cancer types, offering detailed insights into the unique cellular and molecular interactionsHighlights current advancements in cancer research, including novel diagnostic techniques and emerging therapeutic strategies that target the tumor microenvironmentIncorporates real-world case studies and practical examples, allowing readers to understand the implications of theoretical concepts in clinical settingsEncourages the application of new strategies to improve patient care in oncology

Emerging Trends in Cancer Research provides a comprehensive and up-to-date exploration of the latest advancements in cancer therapeutics, diagnostics, and intellectual property landscapes. Each chapter delves into the specific aspects of different cancers, offering insights into drug resistance mutations, biomarker trends, preclinical model updates, and clinical pipeline developments. The book also addresses the importance of diagnostics and the evolving landscape of intellectual property in cancer treatment. Sections analyze cancer drug resistance mutations, biomarker trends, and diagnostics across various cancers, including intestinal, cardiac, brain, and blood cancers.Readers will find coverage of clinical pipeline developments, intellectual property landscapes, and advancements in cancer therapeutics, diagnostics, and global drug delivery trends. This book is an invaluable resource for oncology, biomedical engineering, and pharmaceutical professionals, offering insights into the latest cancer research trends. It includes real-world case studies, practical applications, and discussions on regulatory and ethical considerations, making it essential for both seasoned researchers and graduate students.Provides comprehensive, up-to-date insights into the latest advancements in cancer therapeutics, diagnostics, and intellectual property landscapes, covering a wide range of cancers (intestinal, cardiac, brain, and blood cancers)Delivers detailed analyses of drug resistance mutations, biomarker trends, preclinical model updates, and clinical pipeline developmentsIncludes real-world case studies and practical applications, along with discussions on regulatory and ethical considerations

Biosimilars in Cancer is a comprehensive resource addressing the role of biosimilars in treating various cancer types. This book offers a succinct yet thorough overview of current trends in oncology, covering 21 different cancers from liver to breast cancer. Each chapter provides detailed insights into the latest trends, fundamental facts, and practical and clinical data, making it an invaluable tool for academics and practitioners. By compiling this rich content into a single, accessible volume, the book empowers researchers and clinicians to enhance their understanding, and improve patient outcomes through the effective use of biosimilars in oncology. Targeted primarily at pharmaceutical researchers, biomedical scientists, and clinicians, Biosimilars in Cancer supports the growing oncology biosimilars market. It also provides critical insights for those involved in cancer diagnostics and clinical trials, helping them stay ahead in this rapidly progressing field.Offers detailed information on 21 different cancer types, ensuring a broad understanding of biosimilar applications in oncologyPresents up-to-date insights into the rapidly evolving field of cancer treatment, helping researchers and clinicians stay aheadIntegrates fundamental facts with practical and clinically relevant data, making it a valuable resource for academic and clinical purposes

Comprehensive yet succinct insight into the prevention, diagnosis, and treatment of infectious diseases including COVID-19, mpox, Ebola, and Lyme diseaseRising Contagious Diseases provides basic information about preventing and treating threatening infectious diseases from viral, bacterial, and parasitic sources, including 28 emerging or recurring diseases like COVID-19, mpox, Ebola, bird and swine flu, malaria, Legionnaires', and others. The text highlights molecular surveillance and epidemiology (including zoonotic pathogens or their variants), innovative strategies for pathogen detection, drug and vaccine development, appropriate preventive measures, cost-effective diagnostic procedures (assays), and effective therapeutic strategies.The text is unique due to its broad coverage of today's infectious diseases, covering several which are not similarly addressed elsewhere, with detailed insight from experts around the world.Composed of 30 chapters of fundamental facts alongside practical and clinical data, Rising Contagious Diseases covers sample topics such as: Re-emergence of certain diseases in recent decades due to dynamic host-pathogen interactions, anthropogenic selection, and climate changeHow real-time epidemiological surveillance can improve detection of infectious disease outbreaks or new infections of public health importanceUp-to-date insight on transmission dynamics, epidemiology, clinical manifestation, advances in diagnostics, and management of covered diseasesEffects of disease outbreaks on the world at large, such as through high morbidity and mortality rates and rising healthcare costsWith detailed insight on the prevention, diagnosis, and treatment of infectious diseases, Rising Contagious Diseases is an essential reference for health care professionals, academics in the field of microbiology, immunology, infectious diseases, pathology, pharmacology and public health, and undergraduates and postgraduates in related disciplines.

The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis. It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy.

The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis. It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy.

This is the only published book which compiles the complete road map of malarial drug delivery systems along with an overview on the pathology, current state of malaria across the globe, new clinical trials, emerging drugs and evolving novel drug delivery platforms.

This is the only published book which compiles the complete road map of malarial drug delivery systems along with an overview on the pathology, current state of malaria across the globe, new clinical trials, emerging drugs and evolving novel drug delivery platforms.

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future.A total of four books are covered under the series of Infectious drug diseases.- Malarial drug delivery systems- Tubercular drug delivery systems- Viral drug delivery systems- Infectious disease drug delivery systemsInfectious diseases are the world’s greatest killers that present one of the most significant health and security challenges. Humans have lived with emerging and re-emerging pathogens since before the documented history of civilization. The only determining fact today is - If the situation is “worse” or “better” than in past. The answer is probably “worse”, may be due significant increase in human population, increased cross-continent mobility, imbalanced (stressed) life style, irregular food habits leading to compromised innate immunity and over or under practiced hygiene routine. When the incidence of such a disease in people increases over 20 years or threatens to increase, it is called an “emerging” disease, and a growing number have made watch lists andheadlines in nearly every country -like highly pathogenic H5N1 avian influenza, severe acute respiratory syndrome (SARS), Ebola virus, food- and waterborne illnesses, and a range of antimicrobial-resistant bacterial diseases TB. This book addresses current and new therapy developments in treating such infectious diseases, updates on finding new drugs, identification of innovative diagnostic methods, understanding of disease research models and clinical trials performances of new treatment modalities.Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of infectious diseases and related research.

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future.A total of four books are covered under the series of Infectious drug diseases.- Malarial drug delivery systems- Tubercular drug delivery systems- Viral drug delivery systems- Infectious disease drug delivery systemsInfectious diseases are the world’s greatest killers that present one of the most significant health and security challenges. Humans have lived with emerging and re-emerging pathogens since before the documented history of civilization. The only determining fact today is - If the situation is “worse” or “better” than in past. The answer is probably “worse”, may be due significant increase in human population, increased cross-continent mobility, imbalanced (stressed) life style, irregular food habits leading to compromised innate immunity and over or under practiced hygiene routine. When the incidence of such a disease in people increases over 20 years or threatens to increase, it is called an “emerging” disease, and a growing number have made watch lists andheadlines in nearly every country -like highly pathogenic H5N1 avian influenza, severe acute respiratory syndrome (SARS), Ebola virus, food- and waterborne illnesses, and a range of antimicrobial-resistant bacterial diseases TB. This book addresses current and new therapy developments in treating such infectious diseases, updates on finding new drugs, identification of innovative diagnostic methods, understanding of disease research models and clinical trials performances of new treatment modalities.Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of infectious diseases and related research.

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity.A total of four books are covered under the series of Infectious drug diseases.- Malarial drug delivery systems- Tubercular drug delivery systems- Viral drug delivery systems- Infectious disease drug delivery systemsThe third volume of series is focused on viral drug delivery systems. Typically, virus attaches to the cells (referred as host cell) and releases its DNA or RNA inside the cell. In second stage, virus’s genetic material takes control of the cell and forces it to replicate the virus leading to onset of disease symptoms. DNA class of viruses include Herpes, Papilloma and Adeno viruses. RNA class of viruses include retroviruses, such as HIV immunodeficiency virus and SARS COV – 2 / Corona virus. This book addresses recent developments in viral drug delivery systems. It covers many different aspects of viral infections, ways to treat them using modern drug delivery systems like nano particulate carriers. The choice of viral delivery systems mainly depends upon the type of virus, duration of life cycle, presence of drug resistance, cellular and mucosal interaction of virus, accordingly gene or non-gene drug delivery systems are selected. Besides that, this book also reports global dynamics of viral diseases, future predictions of infection rate, current treatment options, details of drug carriers like nanoemulsions, polymeric nanoparticles, role of biofunctionalization, and phyto-molecules in treatment of viral infections particularly herpes, Covid-19, Ebola, HIV/AIDS, influenza and viral hepatitis.Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of viral drug delivery research.

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity.A total of four books are covered under the series of Infectious drug diseases.- Malarial drug delivery systems- Tubercular drug delivery systems- Viral drug delivery systems- Infectious disease drug delivery systemsThe third volume of series is focused on viral drug delivery systems. Typically, virus attaches to the cells (referred as host cell) and releases its DNA or RNA inside the cell. In second stage, virus’s genetic material takes control of the cell and forces it to replicate the virus leading to onset of disease symptoms. DNA class of viruses include Herpes, Papilloma and Adeno viruses. RNA class of viruses include retroviruses, such as HIV immunodeficiency virus and SARS COV – 2 / Corona virus. This book addresses recent developments in viral drug delivery systems. It covers many different aspects of viral infections, ways to treat them using modern drug delivery systems like nano particulate carriers. The choice of viral delivery systems mainly depends upon the type of virus, duration of life cycle, presence of drug resistance, cellular and mucosal interaction of virus, accordingly gene or non-gene drug delivery systems are selected. Besides that, this book also reports global dynamics of viral diseases, future predictions of infection rate, current treatment options, details of drug carriers like nanoemulsions, polymeric nanoparticles, role of biofunctionalization, and phyto-molecules in treatment of viral infections particularly herpes, Covid-19, Ebola, HIV/AIDS, influenza and viral hepatitis.Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of viral drug delivery research.

The Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems (DDS) in targeting drugs in the intraperitoneal (IP) cavity.There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (<20 kDa) is not sufficiently long to maintain therapeutic effect. This leads to frequent or continuous dosing. Another challenge is device-related or catheter-related problems, such as catheter obstruction, increased risk of infection, and bowel complications. Overall literature shows that the IP site is satisfactorily explored by clinicians but in terms of drug delivery not that much. One can see a clear-cut gap of expertise exchange between the two fields and guidelines from regulatory lawmakers on new medications.In summary, challenges like delivery to IP cavity, tumor or organ-specific targeting, efficient tissue penetration, optimal cellular uptake and intracellular residence of a drug, biocompatibility, toxicity, etc can be easily solved by smartly designing functional drug delivery systems (both nano and micro). Nanotechnologies have always fascinated humans for several decades and are now widely explored in the biomedical field. Diverse types of nanoparticles are being explored around the world, some examples include biodegradable nanoparticles, green nanoparticles, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, graphene, carbon nanotubes, and several others. Now a day's nanoparticles are gaining interest for drug targeting of chemotherapeutic drugs, immunotherapy, and gene delivery. Whereas microparticles can be explored for delayed drug delivery to the peritoneal cavity due to relatively slow removal from IP fluid. Hydrogels or other adhesive drug delivery may help to enhance peritoneal adhesions; thereby maintaining the balance between benefit and risk. Overall, drug delivery systems are key in IP targeting. That means drug delivery specialist and clinician needs to be connected to get the best out of this route of drug administration.The present book is a link between pharmaceutical scientists (drug formulators), clinicians, toxicologists, and regulatory experts. This book also provides a new perspective to researchers to divert or guide their research in an optimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially in the medical devices sector to face up and show potential in delivering drugs. It is a chance for commercial partners like insurance companies and the pharma industry to explore this direction.